A medtech start-up with a leading CE-marked product faced a strategic resource allocation decision: invest in next-generation technology in the current low-growth market, or place bets on riskier technologies in the emerging higher growth segment?
RNA undertook a comprehensive strategic and commercial operations review, including market segmentation, competitive analysis, assessment of investor interest, comparable transaction analysis, and impact on exit strategies. The insights gained led RNA to recommend that the company extend its leading clinical position to the newer, faster-growing opportunity. Careful analysis also revealed an opportunity to reallocate funds from underperforming commercial territories to bring the next-generation technology across the finish line.
With RNA’s help, the company was able to confidently commit sufficient investment to have two “shots-on-goal” in the new market segment. At the same time, thoughtful cost control provided the resources to fully pursue the product iteration, pleasing the existing customer base.
By acting as outsourced Corporate Strategy, RNA Advisors provided management with a cost-effective way to make mission-critical decisions and communicate those strategies to the company’s Board of Directors, customer base, and investment community.